Heparin

EMA’s safety committee ( PRAC ) has concluded that a warning about unusual blood clots with low blood platelets should...


Results from the phase III EINSTEIN-Jr. study has shown a strong efficacy and safety profile of Rivaroxaban ( Xarelto )...


Anthracycline-induced cardiotoxicity was first reported in early 1970s. Since then, there has been increasing recognition of its association with poor...


The FDA ( Food and Drug Administration ) has approved the first pacemaker that does not require the use of...


The European Society of Cardiology ( ESC ) has recommended uninterrupted anticoagulation with vitamin K antagonists during ablation and device...


Non-vitamin K antagonist oral anticoagulants ( NOACs ) are efficacious and safe antithrombotic drugs but the non-availability of an antidote...


The efficacy and safety of Dabigatran ( Pradaxa ) for treatment of venous thromboembolism ( VTE ) were demonstrated in...


Most ischaemic strokes are caused by a blood clot blocking an artery in the brain. Clot prevention with anticoagulants might...


Two separate clinical trials were presented as a part of ACC.15, and looked at strategies to reduce major bleeding and...



The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) issued...


A study has examined the efficacy and bleeding outcomes of Cangrelor ( Kengrexal ) in patients in the CHAMPION PHOENIX...


The phase II RADAR-PCI study has determined the feasibility of conducting percutaneous coronary intervention ( PCI ) in high-risk acute...


Bivalirudin is an alternative to Heparin in patients undergoing percutaneous coronary intervention ( PCI ). A meta-analysis of randomised...


The results from the STRATUS trial ( MM-010 ), a single-arm phase IIIb study of Pomalidomide ( Imnovid, Pomalyst )...


A new study has compared outcomes for two drugs used to prevent blood clot formation during emergency myocardial infarction treatment....


The European Medicines Agency ( EMA ), the Committee for Medicinal Products for Human Use ( CHMP ), and the...


Venous thromboembolism ( VTE ) often complicates the clinical course of cancer. The risk is further increased by chemotherapy, but...


For patients with atrial fibrillation or atrial flutter of 48-hour duration or longer, or when the duration of atrial fibrillation...


Pradaxa ( Dabigatran etexilate ) has been approved by the European Commission for the treatment and prevention of recurrence of...